startup.bid
DA
EnglishEspañolPortuguêsFrançaisDeutschItalianoNederlandsSvenskaDanskNorskPolskiSlovenščinaTürkçeРусскийBahasa IndonesiaBahasa MelayuFilipinoTiếng ViệtKiswahiliहिन्दीاردوالعربيةעברית日本語한국어中文繁體中文

Rejuvenation Technologies Inc.

mRNA therapeutics to extend healthspan entering clinical trials

Om virksomheden

Virksomhedsbeskrivelse på engelsk

Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.

Emner

Anti-AgingGene TherapyNanomedicineHealthcareTherapeutics
Sted
San Francisco, CA, USA
Teamstørrelse
2 ansatte
YC-batch
Summer 2018
Status
Aktiv
Fase
Tidlig fase

Lignende startups og konkurrenter

Spørgsmål og svar

Hvor holder Rejuvenation Technologies Inc. til?

San Francisco, CA, USA

Hvor mange arbejder hos Rejuvenation Technologies Inc.?

Antal ansatte ifølge virksomhedsprofilen: 2.

Har Rejuvenation Technologies Inc. rejst kapital?

Der er ingen investeringsrunder for Rejuvenation Technologies Inc. i vores data.

Hvilke alternativer er der til Rejuvenation Technologies Inc.?

Lignende startups: Sixfold Bioscience, Nuntius Therapeutics og 64x Bio.